Bate, C., Salmona, M. and Williamson, A. (2004) The role of platelet activating factor in prion and amyloid-beta neurotoxicity. NeuroReport, 15, pp. 509-513. (doi: 10.1097/01.wnr.0000113065.17279.7b)
Full text not currently available from Enlighten.
Abstract
In the prion diseases, neurodegeneration is preceded by the accumulation of the disease-associated isoform of the prion protein (PrP). In the present study, neurones treated with three different phospholipase A2 inhibitors were resistant to the toxic effects of PrP peptides or a synthetic miniprion (sPrP106). Phospholipase A2 inhibitors also protected neurones against a toxic peptide found in Alzheimer's disease (amyloid-beta1-42). Further studies showed that neurones pre-treated with platelet activating factor (PAF) antagonists were equally resistant to PrP peptides or amyloid-beta1-42. Moreover, both phospholipase A2 inhibitors and PAF antagonists reduced the activation of caspase-3, a marker of apoptosis, and the production of prostaglandin E2 that is closely associated with neuronal death in prion or Alzheimer's diseases
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Williamson, Ms Avril |
Authors: | Bate, C., Salmona, M., and Williamson, A. |
College/School: | College of Medical Veterinary and Life Sciences |
Journal Name: | NeuroReport |
Publisher: | Lippincott Williams & Wilkins |
ISSN: | 0959-4965 |
ISSN (Online): | 1473-558X |
University Staff: Request a correction | Enlighten Editors: Update this record